This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Rebecca Lumley
18 May 2022

Pharma Supply Chain People Moves

The latest appointments and promotions across the pharmaceutical supply chain.

May 2022:

Global contract research organisation BioAgilytix Labs, LLC has appointed healthcare executive David King to its Board of Directors. King is the former Executive Chairman and CEO of Laboratory Corporation of America Holdings (Labcorp). He led Labcorp's transformation from a pure-play US testing laboratory into a leading global life sciences company. He joins BioAgilytix as the CRO embarks on a major expansion of its services, including the creation of hundreds of new scientific roles across the company. 

'I'm thrilled to join BioAgilytix at such an exciting juncture in its journey. I very much look forward to working with the Board and the great BioAgilytix team to build on the organisation's impressive track record of success,' King said. 

BioAgilytix also announced the appointment of Lynn Kamen and Michelle Miller as scientific officers. Between them they bring more than two decades of experience in drug discovery, development and immunology, and toxicology.

Kamen is an immunologist who most recently worked at Genentech as a principal scientist within the Development Sciences organisation, leading the bioanalytical analysis for large molecules for late-stage research through the clinic, while Miller worked with BioAgilytix previously as a bioanalytical associate director. Prior to joining the company, Miller led GLP toxicology and immunotoxicology studies and developed high throughput screening assays as lead investigator. She also worked as an R&D scientist in the pharmaceutical industry. 

Speaking about the appointments, BioAgilytix Chief Scientific Officer Jim McNally said: 'We are delighted to welcome Lynn and Michelle to our team. They will both be valuable assets to our internal teams and partners to our clients. Their experience with drug development and bioanalytical support will immediately add value to BioAgilytix'. 

Michelle Miller (L) and Lynn Kamen (R)

Abzena has appointed Dr. Petra Dieterich, DPhil, MBA as its new scientific lead. She will report to the company's chief technology officer, Dr. Louise Duffy, and will support Abzena's drug development and manufacturing operations. Dr. Dieterich most recently served as senior vice president at Aptuit Oxford, a pharmaceutical services provider that offers early discovery to mid-phase drug development solutions. 

April 2022:

Exelixis has announced that co-founder Charles Cohen, Ph.D. will retire from the Board of Directors, choosing not to stand for re-election at the company's 2022 AGM in May. His resignation from the Board will take effect on the day of the meeting. Dr. Cohen is an independent investor and former biopharma chief executive officer who has served on the company's Board of Directors since November 1995. 

Osivax appoints Dr. Michael Watson, former president of Moderna's vaccine division, to its Board of Directors. He joins the company as it advances its influenza vaccine candidate through Phase 2 clinical studies and prepares to enter the clinic with its universal coronavirus vaccine candidate, OVX033. Osivax is a biopharma company focused on developing vaccines to protect against highly mutating infectious diseases. Dr. Watson is currently the Executive Chairman of VaxEquity and CEO of MEVOX, two companies specialised in vaccine development. 

CARsgen Therapeutics appoints Dr Raffaele Baffa as Chief Medical Officer, where he will oversee global clinical development strategies and operations for the company's pipeline product candidates. Prior to joining CARsgen, which focuses on CAR T cell therapies, Dr Baffa served as Chief Medical Officer and Executive Vice President of Research and Development at Ziopharm Oncology, recently rebranded as Alaunos. 


OGT appoints Adrian Smith as CEO from April 1. Smith joins OGT, a provider of clinical and diagnostic genomic solutions, from diagnostic and medical imaging solutions company Hologic, where he was General Manager of the UK and Ireland. The appointment comes as Dr John Anson retires from his position as CEO and member of the Board, after more than 16 years with the company. 

Smith commented: "I'm excited to join OGT at this moment in the company's development. John has done a fantastic job steering this team - it's rare to come across a company so passionate and dedicated to partnering with its customers to improve clinical care". 


March 2022:

MedPacto appoints global clinical expert and former lead clinician at KaryoPharm, Dr. Timothy R. Allen, as EVP of Clinical Development. Dr Allen is a clinical expert in the field of oncology, who most recently served as Vice President of Clinical Development at KaryoPharm. 

Neuraxpharm Group announces the appointment of Monica Torrecilla as Country Manager for Portugal, reinforcing the company's push to increase its management team in Europe. In the new role she will focus on expanding the company's position in key areas and adding to the current portfolio on schizophrenia and sleep disorders, as well as the new launches on epilepsy and depression.

Avacta Group, a clinical stage biopharmaceutical company developing cancer therapies, announces the appointment of Christina Coughlin as Non-executive Director to the Board with immediate effect. Coughlin is the CEO of CytoImmune Therapeutics, which focuses on the development and commercialisation of novel cancer immunotherapy products. 

PCI Pharma Services appoints John Cullivan as a new member of the Executive Leadership Team in the role of Chief Corporate Development Officer. Cullivan will play a key role in PCI’s growth strategy, with a particular focus on M&A, focusing on acquisitions to enter new markets and geographies, and strengthen PCI's portfolio of client solutions.

Awakn Life Sciences, a biotech focused on the research, development, and delivery of psychedelic therapeutics to treat addiction, announces the appointment of Kevin Lorenz as their new U.S. Head of Commercial Development. Lorenz will lead Awakn’s therapeutics commercialisation activities in the United States, starting with the launch of its Licensing Partnership business.


February 2022:

LEO Pharma announces the appointment of Brian Hilberdink as Exectuive Vice President and President of LEO Pharma Inc., in the United States. Hilberdink joins LEO Pharma from Novo Nordisk, where he served as Senior Vice President of Sales for the U.S.

DFE Pharma announces that Martti Hedman has been appointed as the new Chief Executive Officer. An experienced business leader, Hedman will succeed Bas van Driel. Hedman is a former CEO of Colorcon, and brings many years of global pharma leadership, having held executive positions in the United States, United Kingdom, Germany, and Finland. He shares:

“I am excited to join DFE Pharma as its new CEO. The company is a global market leader in its excipient categories. I am looking forward to working with all my new colleagues and taking the company to the next phase. I am especially pleased to know that DFE Pharma plays a key role in the COVID-19 therapies – both in vaccines and in solid oral dosage forms”.

ApiJect Systems, a medical technology public-benefit corporation, whose platform helps pharmaceutical and biotech companies efficiently fill-finish and deliver their injectable medicines in prefilled delivery systems, announced today the hiring of new Chief Technology Officer, Products, Molly Weaver, PhD. Dr Weaver most recently served as Vice President for Containment Systems & Portfolio Management at West Pharmaceutical Services, and is a seasoned industry leader whose background includes pharmaceutical and medical technology. Her leadership and expertise spans strategy, product development, and execution across a broad range of industrialization and drug delivery systems. 

Stevanato Group announces the appointment of Riccardo Butta to the role of president, Americas. The appointment of a dedicated executive to lead the company’s long-term strategy in the Americas is indicative of the company’s commitment to broaden its footprint, accelerate its market penetration and improve proximity to its customers in the US. Butta joins the group with more than 30 years of management experience, including 20 years with CDMO, Flex Ltd.

SK Capital Partners, a private investment firm focused on the specialty materials, specialty chemicals and pharmaceuticals sectors, today announced the hiring of Anne Kolton as its first Chief Sustainability Officer. Ms. Kolton will chair the SK Capital Sustainability Board, composed of a subset of SK Capital’s portfolio company CEOs and Managing Directors that oversee SK Capital’s Sustainability Program. She will also lead the Sustainability Council of SK Capital, consisting of 21 Sustainability leaders representing each of SK Capital’s portfolio companies. Ms. Kolton has 20 years of advocacy, issues management and sustainability experience, integrating strategy development, cross-industry and cross-value chain collaboration, industry and public policy development, legislative and regulatory government relations and strategic communications. She also previously served as a White House Spokesperson, an Advisor to the Chair of the Securities and Exchange Commission, and as Director of Public Affairs at the U.S. Department of the Treasury and U.S. Department of Energy.

January 2022:

Galapagos NV announces the appointment of Dr. Paul Stoffels as Chief Executive Officer, effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas. He will succeed current Chief Executive Officer and co-founder Onno van de Stolpe, following planned retirement. Stoffels was previously Chief Scientific Officer at Johnson & Johnson since 2012 and led development of its single-shot COVID-19 vaccine which won U.S. regulatory authorization in February last year.

GlaxoSmithKline's top scientist, Hal Barron, will leave the British drug-maker to become CEO of Silicon Valley based start-up Altos Labs. He will transition into a Non-Executive Director at GSK role in August 2022. Tony Wood will replace Barron as Chief Scientific Officer, assuming full responsibility for R&D. Emma Walmsley, Chief Executive Officer said: “We are delighted to appoint Tony as our next CSO. He is an outstanding scientist who is highly respected inside and outside GSK. Tony has been a key partner to Hal in delivering our R&D approach, and with his experience and expertise across science, data and new technologies, he is perfectly placed to build on Hal’s outstanding progress and to deliver value from our pipeline. Hal’s appointment to Altos Labs is a unique opportunity for him and we are pleased that GSK will continue to benefit from his expertise at the Board and in support of R&D. Altogether, these changes provide us with a clear pathway for continued momentum in R&D to deliver our new ambitions for growth and scale impact for patients.”

Adare Pharma Solutions Announces Appointment of Tom Sellig as Chief Executive Officer. Sellig, a 30-year veteran of the pharmaceutical and life sciences industries, will lead the organization in supporting pharmaceutical companies in the development and manufacturing of transformative medicines that improve patient health and outcomes. The announcement of Sellig’s appointment comes on the heels of Adare’s acquisition of Frontida BioPharm, which expanded Adare’s global footprint to seven manufacturing and R&D sites dedicated to contract services for the pharmaceutical industry. Adare is backed by private equity firms Thomas H. Lee Partners, L.P., and Frazier Healthcare Partners.

Catalent announces that its Board of Directors has appointed Alessandro Maselli, currently President and Chief Operating Officer, as the company’s next President and Chief Executive Officer, effective July 1, 2022. Maselli will also join the company’s Board of Directors upon assuming his new role. Current Chair and Chief Executive Officer John Chiminski will remain in his present role until July 1, 2022, when he will assume the position of Executive Chair of the Board.

November 2021:

Alcami has appointed Timothy Compton as Chief Business Officer. Mr. Compton, who brings over 25-years of industry experience leading high-performing business teams, will be responsible for driving the continued growth of Alcami's service offerings. 

Prior to joining Alcami, Mr. Compton was the Chief Commercial Officer at Avid Bioservices. From 2015 to 2019, he was the Vice President of Sales and Marketing at Avista Pharma, a private equity-owned CDMO acquired by Cambrex Corporation in January 2019.

AGC Biologics says Jean-Baptiste Agnus has been appointed as the company’s Chief Business Officer (CBO). In this position, he is responsible for strategic leadership over all aspects of the company’s global business development and sales and marketing teams. Mr. Agnus brings more than 20 years of experience in biopharmaceuticals and contract development and manufacturing. He joins AGC Biologics after three years with Ajinomoto Bio-Pharma Services, where he led the company’s strategic vision of its worldwide sales and marketing activities. Prior to that, he worked for 13 years at Novasep, and held a number of business development leadership roles with increasing responsibility both in Europe and the US.

October 2021:

Rentschler Biopharma has appointed Dr. Robert Panting as General Manager of Rentschler ATMP Ltd. Center of Excellence in Stevenage, UK, Europe's largest cell and gene therapy hub. It was set up to address the gap in capacity and support for early-stage innovators in cell and gene therapy. In this position, Dr. Panting will manage all operations at the site.
Prior to joining the company, Dr. Panting spent ten years at Fujifilm Diosynth Biotechnologies, where he held positions in the areas of project management, customer management and business planning. Most recently, as Vice President for Program Management and Sales & Operations Planning, he focused on driving delivery of client projects and overseeing short- and long-term planning for the company’s UK operations.

Alcami has announced the appointment of three additions to their senior leadership team. Chad Bovero has been appointed to the role of Vice President, Charleston Sterile Operations, James Fife has been appointed to the role of Vice President, Validations and Metrology and Tobin Cowart has been appointed to the role of Senior Director, Technical Services.

Mr. Bovero began his career in the United States Air Force as a Calibration Technician and brings a depth of technical expertise and a track record of leading sterile manufacturing operations. Before joining Alcami in July, he was the Director of Operations at LSNE Contract Manufacturing. Previously, he held roles as the Filling and Lyophilization Manager at Xellia Pharmaceuticals and Biologic Operations Manager at Pfizer.

Mr. Fife returns to Alcami after spending three years at Exela Pharma Services LLC as Executive Director of Manufacturing Operations and, most recently, as Vice President of New Initiatives and Opportunities. He brings over 25 years of sterile manufacturing experience and various leadership roles at Cardinal Health, Akorn, Amylin Pharmaceuticals, and Grand River Aseptic Manufacturing.

Mr. Cowart returns to Alcami after spending four years at Exela Pharma Services as Director of Technical Services. Before this, he spent 20 years at AAI Pharma Services (Alcami) in various validation, engineering, process development, manufacturing, and technical service roles.

August 2021:

Sharp, a part of UDG Healthcare and a leading provider of pharmaceutical packaging and clinical services, has appointed Paul Thomas as Business Development Manager for its UK commercial services. Reporting to Jeff Benedict, Chief Commercial Officer, Mr Thomas has taken responsibility for generating commercial packaging sales at Sharp’s Rhymney site in South Wales and will also work alongside European BD colleagues supporting Sharp’s Belgian and Netherlands facilities. Mr Thomas, who joins Sharp from Westfield Medical Ltd, has over twenty years’ experience in healthcare and pharma packaging sales. In the past, he has worked for Aptar Pharma where he was responsible for the commercial device development for Narcan®, an overdose rescue medicine, which was approved by the FDA in 2015.  He has also held roles at Bemis Healthcare Packaging, Budelpack and GE Healthcare in Cardiff, where he was Packaging Development Manager.

Altasciences has appointed Dr Bruce Frank as Vice President, CDMO Operations. Dr Frank has 30 years of experience with product formulation and development, leading discovery chemistry, new technology evaluation, and project management initiatives, in both small and large biotechnology firms. At Altasciences, he will oversee the Manufacturing, Formulation, and Analytical teams, applying his most recent experience from Lubrizol Life Sciences to maximize client experience and streamline early phase drug development.

Ashfield Health, a global healthcare marketing and communications network and part of UDG Healthcare, has named William Martino (below) as Growth Director, North America. In this new role, Martino will lead the business development for Ashfield Health and Mind+Matter, an Ashfield Health agency. Mr Martino has more than 20 years of leadership in healthcare marketing, including pharmaceuticals, OTC, animal health, and health technology. Before joining Ashfield Health, he served as the chief growth officer at Wunderman Thompson Health, and during his tenure, served in a variety of management, strategy, and account roles.

CRO Quanticate has named Piotr Karasiewicz as the company’s new Head of Machine Learning and Digital Transformation to lead process improvements and ensure efficient and high-quality data analysis. Reporting to Chairman and Chief Executive Officer David Underwood, Karasiewicz will lead the execution of technology strategy with specific focus on the research and development, and optimization of, new and existing products.

July 2021:

Bora Pharmaceuticals has appointed Sally Langa as its new Global SVP Sales and Marketing to help drive the company’s continued growth and achieve its aggressive expansion plans. Bringing a wealth of experience within the highly competitive contract manufacturing industry, she has held several senior roles in some of the industry’s most prominent CDMOs. Ms Langa, who will report directly to Bobby Sheng, Bora’s Chairman and CEO, will be responsible for building the overarching strategy and roadmap for Bora Pharmaceutical’s CDMO services.

June 2021:

Cleanroom microbiology solutions provider Cherwell Laboratories has promoted Steven Brimble (below) to the newly created role of Director of Quality and Technology, with a core focus on product innovation and continual improvement. He has worked for the past five years as Cherwell’s Quality Manager, is a Practitioner with the Chartered Quality Institute, and was also formerly the National Quality Manager for Public Health England Food, Water & Environmental Microbiology.

Abzena has appointed Patrice Dudley Aviles as the Chief Human Resource Officer. With over 25 years’ experience in the pharmaceutical industry, she has previously held roles at Pfizer, Amgen, Alexion, and Genentech.   At her previous company, Genentech, she was the Global Human Resources Business and North America Human Resources Leader to Pharma Technical Operations.

CDMO Recro Pharma has appointed Laura Parks to the company’s board of directors. Dr. Parks most recently served on the executive leadership team at Patheon until its acquisition by Thermo Fischer Scientific in 2017. In this role, she led strategic commercial and operational initiatives including development and execution of an end-to-end pharmaceutical services offering, as well as global strategic enterprise accounts organization. Prior to her role with Patheon, she served as president of DSM Pharmaceuticals, the $250 million steriles and oral solid finished dose CDMO of DSM, until its 2014 merger with Patheon. Dr. Parks was also senior vice president, marketing and sales for DSM Pharmaceuticals, during which time she successfully led the marketing and sales team in support of the business unit’s world-class contract manufacturing services for finished dose pharmaceuticals, including sterile injectibles, orals, topicals, as well as developmental services.

CMO Symbiosis Pharmaceutical Services, which specialises in sterile manufacture of vaccines, pharmaceuticals and biopharmaceuticals, and headquartered in Stirling, UK, has appointed Jette Cowan as Business Development Manager for the Northern region of the European Union. She brings to Symbiosis decades of business development success, plus key experience gained from roles with several prominent European life science companies.

Selexis SA, a JSR Life Sciences company, has named Roland Hoffmann-Hecht as its new chief business officer. As a member of the company’s executive leadership team, Dr. Hoffmann-Hecht will be responsible for all corporate and business development activities and will report directly to Selexis Chief Executive Officer Dirk Lange. He joined Selexis from Polpharma Biologics where he was head of business development, CDMO Europe. Previously, he was chief customer officer at CDMO start-up biopharmaceuticals company, Halix B.V.

May 2021:

Adare Pharma Solutions has hired Robert Muschert as Chief Commercial Officer, and Dr. Vipan Dhall as Chief Scientific Officer, expanding its executive leadership team. Mr Muschert brings nearly 30 years of pharmaceutical industry experience to Adare. His career has spanned business development and sales, supply chain and manufacturing operations, strategic procurement, and technical services in global pharmaceutical and services organizations. Most recently, he was Head of Sales, US Global Account Management Lonza, where he oversaw account management and business development for the company’s east coast partners and new business relationships. Dr. Dhall has more than 25 years of pharmaceutical development experience in traditional pharma as well as the CDMO space. Prior to joining Adare, he was Vice President of Life Sciences, North America at SGS. 

ACG has appointed two senior executives  at its R&D facility in Germany. Daniel Illmer joins as design head – encapsulation, and Afsaneh Nakhavoli as design head – tableting. Both join the company’s R&D facility in Germany. Mr Illmer will oversee product development, maintenance, improvements, redesign, and will report to Werner Bongers, CEO, SciTech, ACG. He joins from Robert Bosch Packaging Technology, where he was responsible for mechanical design, development, and engineering among other areas. Ms Nakhavoli’s new role as design head – tableting will include leading innovation and product development, with the same reporting lines. In the last seven years as a project engineer at Fette Engineering GmbH, she led the development and construction of automatic capsule-filling machines.

Pharmaceutical packaging and clincial services provider Sharp has appointed Walter Tyrrell as chief financial officer and Robert O’Beirn as senior vice president and commercial director.  Mr. O’Beirn takes interim responsibility for Sharp’s European commercial packaging operation, while also leading corporate development overall for the division. Mr. Tyrrell moves to Sharp from within the wider UDG Healthcare group, where he has been Head of Internal Audit since 2014.  Prior to joining UDG Healthcare, Walter held senior roles in the banking and life assurance sectors. Mr O’Beirn joined UDG Healthcare in 2011 as senior legal counsel, later joining the corporate development area, with particular focus on M&A.

CDMO Woodstock Sterile Solutions has named Oliver Vogt as Vice President and General Manager – Site Operations. Mr Vogt has previously served as General Manager for Woodstock and its predecessor, Catalent, for the past three years. In his new role, he is responsible for Woodstock’s manufacturing business as well as leading its supply chain and site operations, including new product development and customer service. Before joining Catalent, he served as the General Manager of Chicago Operations for Adello Biologics; the Vice President of Manufacturing Operations for Merz North America; Director of Global Process and Equipment Engineering for Hospira, and he also had stints at TEVA Pharmaceuticals and Abbott Laboratories.

April 2021:

Adare Pharma Solutions has announced that Ludger Roedder has joined the organization in the newly created role of President of Adare Biome. He will assume responsibility for the entire Microbiome business and serve as a member of Adare's Executive Leadership Team. He brings over 30 years of global business and marketing leadership to Adare and expertise in animal and human nutrition including probiotics and enzymes. He has successfully led business growth through commercial development and successful M&A in Europe, Asia, South America, and the US in the animal and human nutrition spaces. Prior to joining Adare Biome, Ludger was Chief Business Officer at BRAIN AG, where he held responsibility to commercialize the business on a global scale and served as a member of the management Board.

Mayne Pharma's CDMO division, Metrics Contract Services, has named Stephanie Emory as Associate Director of Pharmaceutical Development. Ms Emory was most recently at the FDA where she reviewed the CMC/Drug Product portions of INDs, NDAs, and industry meeting packages for CDER’s Office of Pharmaceutical Quality. Prior to the FDA she spent seven years at UPM Pharmaceuticals, a then Baltimore-based CDMO, serving as both technical lead and project manager for the development of Pre-clinical through Phase III clinical supplies.

AGC Biologics has appointed Jun Takami as General Manager/Site Head at its Chiba, Japan site. Mr. Takami transitioned from his previous role as Project Manager Director at the Japan facility – a role he assumed in 2017 when joining AGC Biologics. He has over 15 years of experience in the pharmaceutical industry, with roles in process development, GMP manufacturing, process engineering and PLI activities with the Roche group at Chugai Pharmaceuticals.

Clinical stage biotech Imvax has named Sean Hemingway (below) as chief operating officer. He will lead the expansion of Imvax's new manufacturing facility at The Curtis and support IT and facilities management functions as well as overseeing manufacturing and supply organisation and building out the company's cell therapy platform. Mr. Hemingway has over 25 years of expereince in biological manufacturing and supply chain. He was previously senior vice president and global head of the BioLife Plasma Services Business Unit at Takeda.

Contract packager Legacy Pharma Solutions has promoted Brad Rayner to President. In his new role, Mr. Rayner’s will be responsible for all of Legacy Pharma Solutions’ sales, operations, quality control and finances. Along with Dave Spence, the company’s Chairman & Majority Owner, Mr. Rayner will set and execute a long-term sales strategy, define target markets and strategically position Legacy for continued growth. In his previous role as EVP, Sales & Business Development, Mr. Rayner was primarily focused on spearheading sales, marketing and customer service teams.

March 2021:

Bioprocess technology provider Univercells Technologies has named Mathias Garny as Chief Executive Officer. Already acting as General Manager, Mr. Garny has been responsible for overseeing the company’s operations and leading the strategy development and implementation. He first joined Univercells in 2015 as Chief Financial Officer before transitioning to Chief Commercial Officer in 2017, playing a key role in Univercells’ development and commercialization efforts of the technology portfolio, including the scale-X single-use bioreactor range and the NevoLine biomanufacturing platform.

ApiJect Systems has appointed Craig Cohon (below) as Chief Strategy Officer. In his new role, London-based Mr. Cohon will lead the company's strategic and brand development in the US and abroad. He has been global advisor to the company since May 2020 and spent 14 years in executive leadership with The Coca Cola Company, spearheading its entry into Russia in 1991 and leading brand work for Coca-Cola globally. He also spent close to a decade owning and leading the Cirque du Soleil business in Russia. 

CDMO Alcami has appointed Patrick Walsh as Chairman and Chief Executive Officer, effective immediately. He succeeds Walter Kaczmarek, who is stepping down. Prior to joining Alcami, Mr. Walsh was co-founder and CEO of TriPharm Services, a parenteral manufacturing business that was acquired by Alcami in January 2020. From 2015 to 2019, he was CEO at Avista Pharma, a private equity-backed global provider of contract manufacturing, development, and analytical testing services. Mr. Walsh also served as CEO of AAIPharma Services Corporation, a predecessor company to Alcami, from 2010 to 2014.

Cell and gene therapy-focused CDMO The Center for Breakthrough Medicines (CBM), has appointed women to four senior leadership positions. Sybil Danby has joined as Senior Vice President of Business Development & Strategy; Eileen Brett is the Vice President of Project Leadership; Dana Cipriano serves as Vice President of Testing and Analytical Services; and Emily Moran is Vice President of Viral Vector Manufacturing. Prior to joining CBM, Ms. Danby spent over three years with responsibility for the strategic business development of Paragon Bioservices, playing an active role in grooming the company for acquisition by Catalent Pharma Solutions in 2019. She also spent two years at Pall Corporation as a driver of the development and sales of disruptive manufacturing technologies, and just under nine years at GSK in both the manufacturing and R&D organizations. Ms. Brett was most recently Head of the Chemistry, Manufacturing and Controls (CMC) Leaders organization for Janssen's Biotherapeutics Development with responsibility for delivering the portfolio of biotherapeutic assets from discovery to post-launch. Ms. Cipriano is creating a testing and analytical services portfolio that enables efficient discovery, development, commercialization, and manufacturing of CGT products, supplying end-to-end solutions for CBM clients and enabling speed to market.  Prior to this position, she was in leadership roles at Wuxi Advanced Therapies for two decades, most recently as Senior Director of Operations & Strategic Projects. Ms. Moran was previously Head of Viral Vector Manufacturing at Lonza delivering both clinical and commercial viral vector products from 50L-2000L scale across multiple modalities. Prior to that, she spent 12 years with Sanofi in applied operational and quality roles of increasing responsibility.

Monique Mendoza

US-based CDMO Pharmaceutics International (Pii) has promoted Monique Mendoza (above) to the position of Head of Quality. She will be responsible for the entire Quality unit at Pii and report directly to the President and Chief Executive Officer, Dr. Kurt Nielsen. Her scope of responsibilities include Sterility Assurance, Batch Disposition, Investigations, Change Controls, Product Complaints, Supplier Qualification, Raw Material Release, Audits (internal, external and client), Document Control, and Quality Control across all facilities including Microbiology Laboratories. ​Prior to joining Pii, Ms Mendoza served as Director of Quality for Dynavax Technologies both domestically and internationally. She also worked for Bayer Healthcare for over 15 years with increasing responsibilities in both Manufacturing and QA.

Shorla Pharma has named Nicholas Holsman as Chief Commercial Officer. A highly experienced US industry executive with in-depth experience in scaling oncology & specialty pharma enterprises, Mr Holsman was most recently Head of Commercial Operations at Oncopeptides, where he was responsible for building the infrastructure to support the launch of Pepaxto, a peptide-conjugated alkylator for the treatment of relapsed and refractory multiple myeloma patients. Before Oncopeptides, Holsman spent nearly four years leading the commercial efforts at KemPharm as Senior Director of Commercial Strategy & Market Access and held roles of growing responsibility at Gilead and Symphony Health.

February 2021:

Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company has appointed Cynthia Pussinen as chief technical officer. Ms Pussinen has more than 25 years of experience in the biopharma industry, leading teams in manufacturing, quality, supply chain, formulation development and process sciences.  As CTO, she will oversee Spark’s manufacturing and technical operations, including pipeline process development, preclinical and clinical manufacturing, and the commercial manufacturing and distribution of Luxturna (voretigene neparvovec-rzyl).

Sai Life Sciences has hired ex-Novartis veteran Dr. Mahavir Prashad as Vice President of Early Phase Process Development. Dr. Prashad is a recognized leader in Chemical Process R&D and leveraging Green Chemistry principles and modern technologies in API synthesis and won the Novartis Leading Scientist award in 2002 and also the 2010 Diversity & Inclusion award of the Novartis Pharmaceuticals Corporation.

Oral solid dosge specialist CDMO Recro Pharma has made a couple of key appointments to its management team and board of directors. The company has named Jim Miller, a highly regarded CDMO industry thought leader, to its board of directors. Additionally, Recro appointed Ryan Lake as chief financial officer (CFO), in late 2020. Mr. Miller is a well-known and highly regarded advisor on drug manufacturing strategy and a pre-eminent authority on the biopharmaceutical CDMO industry. He is founder and former president of PharmSource,, which was sold to Global Data, a London-based provider of market intelligence services in 2016. Prior to joining Recro, Mr. Lake served as CFO and vice president of finance of Aspire Bariatrics, a commercial-stage medical device company.

BioDuro-S undia has appointed Haijun Dong as Chief Executive Officer, taking over from Cyrus Mirsaidi.  The executive team, now led by Mr Dong, will continue to be co-located in both China and the US. Mr Dong has been a General Manager & CEO in China for over ten years, with experience in large multinational companies, including Roche and Eli Lilly. Mr Mirsaidi will continue to serve as Advisor to BioDuro-Sundia’s Board of Directors and leadership team.

Albany Molecular Research (AMRI) has announced the appointment of Scott Waldman as senior vice president, Corporate Development. Mr Waldman will drive key growth initiatives globally, including mergers and acquisitions, and serve as a member of the company’s executive committee. Most recently, he served as an advisor to private equity firms and select pharma industry clients. and previously worked in a number of executive roles at Lonza Group, including chief strategy officer where he led Lonza’s M&A activities.

Metrics Contract Services has appointed Britton Jimenez as Vice President of Business Development. He is responsible for marketing and sales in an executive leadership capacity to support the growing demand for novel oral solid dosage (OSD) projects. Mr Britton joins from Catalent Pharma Solutions, where he was Global Director of Business Development, and he will report to John Ross, President of Mayne Pharma US and Metrics Contract Services.

January 2021:


UK topical and transdermal specialist MedPharm has launched its Scientific Advisory Committee, headed by company founder and board member, Professor Marc Brown (above). Mr Brown has served as MedPharm’s Chief Scientific Officer for over 20 years and will be stepping down from his CSO role to chair the newly formed committee. Comprised of international experts, the SAC will ensure that MedPharm continues to provide clients with scientific services and access to strategic alliances. Dr Jon Lenn (below) will take over the role of CSO, with responsibility for MedPharm’s global scientific operations. Dr Lenn is well established as an authority in the development and optimization of topical products and has played a critical role in MedPharm's growth as well as the development and success of the Durham, NC site.

AGC Biologics has appointed David Stewart as General Manager/Site Head to oversee the startup, strategic development and operational excellence in large-scale biologics production at its Boulder, Colorado site, effective February 1. He also brings more than 20 years of leadership experience in the biotechnology and manufacturing industry, including roles with Biogen and Genentech.

CRO Quanticate has named Lee Patterson as the company's Chief Operating Officer. Reporting to Chairman and Chief Executive Officer David Underwood, Mr Patterson will work across Quanticate's global office network (UK, North America, India, South Africa, and Poland).

With data-focused solutions growing in importance in response to the trend towards virtual and decentralised trials, patient centricity and more efficient monitoring techniques, Mr Patterson will help guide and implement innovative tools, services and approaches with a constant focus on quality.

Sanofi has announced the appointment of Karl Rotthier as the chief executive officer of its newly formed European API unit, EUROAPI, effective January 18th. Mr Rotthier was most recently the Chief Executive Officer of Centrient Pharmaceuticals, and will lead the creation of EUROAPI, which will employ 3,200 skilled employees and be headquartered in France. A planned IPO on Euronext Paris will be evaluated with a decision expected by 2022, subject to market conditions.

December 2020:

Novavax has appointed Rick Crowley to the newly created position of Executive Vice President, Chief Operations Officer. In this role, Mr. Crowley will have leadership responsibility for all operations, including Quality, Manufacturing, Supply Chain and Regulatory Affairs. He takes over manufacturing from Ben Machielse, who will continue with the company as an executive advisor to the Chief Executive Officer, supporting the development of the COVID vaccine. Prior to joining Novavax, Mr. Crowley was Executive Vice President, Technical Operations for TerSera Pharmaceuticals, where he was responsible for technical support as well as development and strategy for the company’s products, created the initial quality systems, and managed all CMC activities.

Injectable platform technology company, ApiJect Systems, has hired James Garrett as its new General Counsel and Chief Compliance Officer. Mr. Garrett joins ApiJect with extensive legal and strategic business expertise, and was previously Senior Vice President for Business and Quality Systems, as well as Government & Regulations Strategy at NuVasive.

Samsung Biologics has appointed John Rim (below), the company’s former Executive Vice President, as the new President & Chief Executive Officer. Mr Rim brings more than 35 years of industry expertise and experience in biopharmaceuticals. Prior to joining Samsung Biologics in September 2018, he served as the head of manufacturing, sales, development department, and as a CFO at global biotech companies like Roche and Genentech.

Catalent has hired Nakaya “Nick” Matsumaru as General Manager of its new clinical packaging facility in Minakuchi, located in the Shiga prefecture of Japan. Reporting to Roel de Nobel, Catalent’s Vice President of Operations for Europe and Asia-Pacific, Mr. Matsumaru joins the company from SymBio Pharmaceuticals, where he held the role of Senior Director Supply Chain & Quality Assurance. Prior to this, he spent four years in vice president, executive officer and head of operations posts with AstraZeneca, and seven years in Japan-based supply chain management with Johnson & Johnson and Janssen.

ACG, a supplier of fully integrated solutions to the pharmaceutical and nutraceutical industry, has appointed Dr. Marcus Michel (below) as the new CEO of ACG Engineering. In his new role, he will be responsible for continuing to drive ACG's focus on the global pharmaceutical industry, innovative technologies, Business Excellence, and Institution Building. He joins ACG from the GEA Group in Germany where he was Executive VP for the entire GEA Pharma Solutions business.

CDMO Frontida BioPharm has appointed Puneet Sapra as new Chief Financial Officer. Mr. Sapra will be replacing Andrew Wang, who recently accepted the CFO role at Frontage Holdings Corporation, a Contract Research Organization based in the US and China. Mr. Sapra has over 20 years of pharmaceutical and healthcare experience in executive roles at Pfizer, Johnson & Johnson, Halma and J.P. Morgan Chase & Co.

November 2020:

CDMO Idifarma, specialising in niche and highly potent drugs, has announced a partnership with Stefano Console from Swiss life sciences consultancy Oriento SA. Bringing with him over 25 years of experience in the pharmaceutical and fine chemical industry, Console will be Idifarma’s scientific advisor focusing upon spray drying technology and particle engineering.

Catalent has named Behzad Mahdavi as Vice President of Open Innovation, Biologics, Cell and Gene Therapy. In this new role, reporting to Julien Meissonnier, Catalent’s Chief Scientific Officer, Dr. Mahdavi will join a team of experts in Catalent’s Science and Technology Group that works with customers and external innovators in both small and large molecules, to accelerate the adoption of new development and drug delivery technologies, and scalable manufacturing processes and techniques. With over 20 years’ experience in developing and implementing growth strategies in the biopharmaceutical industries, Dr. Mahdavi joins Catalent after a 13-year career at Lonza, where he held the role of Vice President Strategic Innovation & Alliances, and various board-level positions at other innovative companies. Prior to joining Lonza, he was Chief Executive Officer of SAM Electron Technologies, a venture capital-backed company in the life sciences field.

Brian Sasaki has joined Pharmaceutics International, Inc. (Pii) as Director of Business Development. He has over 20 years of experience in the pharmaceutical industry and is responsible for Pii’s business development operations in the Western Region of the United States. He began his career as a bench scientist with Bayer Corporation. His range of experiences includes roles with Pfizer, Takeda/Abbott, GE, Lonza, Catalent, and Rapid Micro Biosystems.

Biopharmaceutical CDMO Cytovance Biologics has named Bin Zhang as Chief Executive Officer. Mr. Zhang served two months as Interim CEO before this formal appointment by the board and will report to Mr. Li Li, founder and Chairman of the Board for Shenzhen Hepalink Pharmaceutical Group (Hepalink). and member of the Board for Cytovance. Mr. Zhang has been with Cytovance as a member of the Board of Directors since 2018. In this role as CEO, he will provide oversight in the implementation of the company’s business strategies in the innovative drug development and contract manufacturing market.

Pierre-Alain Ruffieux has now started his role as Chief Executive Officer of Lonza, announced in June. Albert Baehny, who has been CEO ad interim since November 2019 will work with Mr Ruffieux to ensure a smooth handover of leadership before returning to his role as Chairman of the Board of Directors.

October 2020:

The Drug, Chemical & Associated Technologies Association (DCAT) has announced the members of its Board of Directors for the fiscal year, November 1, 2020 to October 31, 2021. Elected as President is Sean Diver, Director, Commercial Development, Small Molecule Drug Substance Lonza. Joining Mr. Diver as officers and Executive Committee members are Kerri McCullough Wood, Senior Vice President, Head of Commercial, Teva API and Medis, who served as 2nd Vice President and Finance Officer. This coming term, she will serve as 1st Vice President for the organization. Sally Macaluso, Vice President & Chief Procurement Officer, Medical Devices and Business Services Procurement, Johnson & Johnson, who served as 3rd Vice President, will become the 2nd Vice President and Finance Officer. Elected to the Executive Committee as the new 3rd Vice President is Charles Davies, Associate Vice President, Global Sourcing & Procurement/Global Pharmaceutical Operations, Merck & Co. Mr. Davies has served as a Director on the Board during the last two years.

August 2020:

SK pharmteco has appointed Joyce Fitzharris (above) as general manager, SK biotek Ireland. She has been leading operations at the company’s Swords Campus in Dublin, on an interim basis since December 2019. She has worked within the Active Pharmaceutical Ingredients business for close to 30 years, previously holding multiple technical and quality management positions with Bristol Myers Squibb and managed Operational Excellence across several affiliated API sites while with BMS and later at SK biotek Ireland.

CureVac has named Franz-Werner Haas, previously acting Chief Executive Officer and Chief Operating Officer (COO), as Chief Executive Officer (CEO). Before Dr. Haas joined CureVac in June 2012, he worked as Vice President Operations and Chief Compliance Officer of SYGNIS Pharma AG, where he was responsible for the execution of M&A and capital market transactions. In addition, CureVac has announced that Igor Splawski joins the executive team as Chief Scientific Officer with immediate effect. In this role, he will be responsible for leading CureVac’s mRNA biology research. Dr. Splawski comes to CureVac from the Novartis Institutes for BioMedical Research (NIBR), where he served for two years as Executive Director and Site Head of the NIBR Biologics Center in Cambridge, Mass.

July 2020:

ApiJect Systems America, a public benefit corporation at the heart of the COVID-19 response, and its subsidiary, RAPID USA, have announced that Franco Negron has joined both organizations, as their new Chief Executive Officer. RAPID stands for “Rapid Aseptic Packaging of Injectable Drugs”. Mr. Negron comes to his new role at ApiJect and RAPID USA after most recently serving as President of Commercial Operations of Thermo Fisher Scientific. He joined the company in 2017 when it acquired his previous employer, Patheon Pharmaceuticals, where he served as President of Development & Commercial, North America. Mr. Negron succeeds ApiJect Systems America and RAPID USA co-founder Jay Walker, who had been serving in the dual role of Chairman and CEO. Mr. Walker will continue to serve as Executive Chairman, with a full-time focus on corporate strategy, product development, and global alliances.

CDMO Bora Pharmaceuticals, which specializes in immediate and modified release tablets and capsules, along with serialized packaging, has announced the appointment of four business development directors to its commercial teams in the US and Taiwan. Mark Dawson joins the team as Senior Director of Business Development. Based on the West Coast of the US in San Francisco, Mark brings a wealth of CDMO sales experience, having worked for Catalent, Eurofins, and Patheon over the last decade. Heading up the Southeast and Mid-West sales in the US, David Scheib joins the team as a Business Development Director. Based in Georgia, David brings almost 20 years of experience in pharmaceutical sales, having worked at Avara Pharmaceutical Services and Recro Pharma. Responsible for the Northeast US and Eastern Canada, Bora welcomes Kalyan Potluri as a Business Development Director. She was formerly a Research Scientist at Pfizer before moving into sales for CDMOs such as Almac. Finally, the company has appointed Wayne Hsiao as Asia Business Development Director. Wayne brings over 17 years' sector experience, previously working in API business development and regulatory technical services at ScinoPharm. He will be responsible for advancing strategic partnerships across Asia.

PMI BioPharma Solutions has announced it will rebrand to August Bioservices afte securing new funding from Oak HC/FT to expand its capabilities to become a specialized, one-stop-shop CDMO for clinical and commercial injectable therapies. PMI has also appointed several industry executives to its leadership team, including Jenn Adams as CEO; Mats Bjoerkman as CFO; Joe Mase as EVP of Operations and Brad Leach as SVP of Commercial Development.

Avomeen has hired Hashim Ahmed (below) as its new Head of Formulation and Manufacturing. In this position, he will further strengthen and expand Avomeen’s formulation and manufacturing segment by partnering with biopharmaceutical clients who are navigating the small- and large-molecule product development life cycle. Most recently, he held a Managing Director position at QLife Pharma. Prior to this, he held leadership positions at Dr. Reddy’s Laboratories, GSK-Stiefel, and Hoffmann-La Roche.

CDMO Cytovance Biologics has promoted Dr. John Mott (below) to Vice President of Development. Dr. Mott will serve on the Senior Leadership Team and report to Dr. Jesse McCool, Chief Executive Officer for Cytovance Biologics.Dr. Mott brings over 35 years of industry experience with bacterial protein expression and over 25 years of experience with mammalian protein expression. Prior to Cytovance, he served as Vice President of Laboratory Services for Aragen Bioscience. During his 30 years at Pfizer, he established the Cell Line Development group.


In this role, Dr. Mott will provide scientific and operational oversight of R&D Services and the Open Innovation team. He will lead the strategic growth of Cytovance, including creating new business opportunities, acquiring cutting edge technologies, and promoting our technical expertise to new clients and partners.

June 2020:

Vaccine developer Novavax has named Ben Machielse as Executive Vice President, CMC, with responsibility for overseeing manufacturing, process technology, quality and regulatory functions. He was most recently Chief Executive Officer of rare disease company Vtesse, before its acquisition by Sucampo Pharmaceuticals, now a part of Mallinckrodt.

Biologics CDMO Avid Bioservices has appointed Nicholas Green president and chief executive officer, as well as a member of the company’s board of directors, effective July 30, 2020. He will succeed Rick Hancock who has served as interim president and CEO since May 2019. Mr. Hancock will continue to serve on Avid’s board of directors. Mr. Green has more than 30 years of experience in the global pharmaceutical and healthcare services industry with expertise in the contract manufacturing of novel pharmaceutical products.

Inovio has expanded its senior management team by appointing two experienced executives to lead its growth in the Asia market and to advance the clinical development of its DNA vaccine INO-4800 to combat the COVID-19 pandemic. Gene Kim joins as President of Inovio Asia, a wholly-owned subsidiary of Inovio based in Seoul, Korea and will report to Dr. J. Joseph Kim, Inovio CEO. Mammen (Anza) Mammen joins as Senior Vice President, Clinical Development, overseeing the clinical development of INO-4800. Dr. Mammen will report to Inovio CSO Dr. Laurent Humeau.

Aldevron has named Kevin Ballinger as Chief Executive Officer, effective July 13. He joins from Boston Scientific, where he served the past nine years as Executive Vice President and Global President of its largest division, Interventional Cardiology. Mr. Ballinger will assume day-to-day operational leadership of Aldevron, facilitating the company’s rapid growth. Meanwhile, Aldevron’s co-founder, Michael Chambers, has been named Executive Chairman of the board. Mr. Chambers initiated the transition to allow him to focus on innovation, corporate strategy and working with clients and industry thought leaders to develop new technologies that enable genetic medicine.

Cambrex has named Tom Loewald as Chief Executive Officer and a member of the company’s board of directors, effective September 7th. As previously announced, in the interim, the company will be led by an Office of the CEO comprised of Wayne Hewett, Chairman of the Board, Robert Green, Executive Vice President and Chief Financial Officer, and Samantha Hanley, Senior Vice President and General Counsel. Mr. Loewald is a 15-year veteran of Thermo Fisher Scientific and currently serves as President of the Flexibles Division of flexible packaging manufacturer ProAmpac.

Moderna has hired Ray Jordan as Chief Corporate Affairs Officer, effective Monday, June 15. He will serve on Moderna’s Executive Committee and report to Chief Executive Officer Stéphane Bancel. Mr. Jordan served as Senior Vice President, Corporate Affairs at Amgen from 2012 through 2019.

Boehringer Ingelheim has appointed Jean-Michel Boers (above) as US Country Managing Director, President and CEO. He will succeed Dr. Wolfgang Baiker, who will retire on July 31 after 31 years at the company. Mr Boers is currently President of Boehringer Ingelheim Pharmaceuticals, having joined in 1998 in Belgium, and advancing through various roles in corporate and operating units, including Corporate Vice President, Marketing and Sales Effectiveness, Country Managing Director for France and Human Pharma head of a European region consisting of mid-sized countries.

Lonza has announced that Pierre-Alain Ruffieux (above) has been appointed Chief Executive Officer effective 1 November, 2020. At that point, Albert Baehny will relinquish his position as CEO ad interim and return to his role as non-executive Chairman. Mr. Ruffieux is currently Head of Global Pharma Technical Operations at Roche. Prior to that he held roles of increasing seniority at Novartis and has over 20 years’ experience in biopharmaceuticals.

CDMO Alcami has named industry veteran Walter J. Kaczmarek III (above) as Chief Executive Officer. He has served in executive roles at sveral pharmaceutical companies, including as President of the Multisource Pharmaceuticals division of Mallinckrodt Pharmaceuticals, COO of Aceto Corporation, and most recently, as President and CEO of Cosette Pharmaceuticals. 

Vectura has appointed Trevor Archbold and Robert Gurley as Business Development Directors with responsibility for Europe and the US West Coast respectively. Additionally, Chris Vernall will join Vectura in August as Business Development Director, and will work alongside Mr Archbold in Europe. All three will report to Mark Bridgewater, who was appointed as Vectura’s Chief Commercial Officer in March 2020. Mr Archbold was most recently Strategic Account Manager at DuPont Pharma Solutions prior to stints at The Dow Chemical Company, Croda and Catalent. Mr Gurley has over 20 years’ CDMO experience, and joins from Cambrex where he was Director of Business Development for the North West territory. Mr Vernall joins Vectura from Nanopharm (part of Aptar Pharma), where he led its business development activities.

Steven Klosk will retire as Chief Executive Officer of Cambrex on June 30 after 28 years with the company. The company’s board is currently in the advanced stages of a search for Mr. Klosk’s successor. In the interim, the company will be led by an Office of the CEO comprised of Wayne Hewett, Chairman of the Board, Robert Green, Executive Vice President and Chief Financial Officer, and Samantha Hanley, Senior Vice President and General Counsel. In addition to Mr. Klosk’s retirement, Shawn Cavanagh will step down as President, Chief Operating Officer and member of the Board of Directors, but will take on the new role of strategic advisor to the incoming CEO and Board of Directors for an initial twelve-month period.

Catalent has appointed Charles Lickfold as Senior Vice President, Chief Information Officer. Mr. Lickfold succeeds John McGill, who, following a period of transition, plans to retire in September 2020. Mr. Lickfold will report to Alessandro Maselli, the company’s President and Chief Operating Officer, and assume responsibility for Catalent’s global IT services and technology. Prior to joining Catalent, he held numerous leadership positions, including Chief Information Officer at Alcami, Avara Pharmaceutical Services, and Gilbarco Veeder-Root.

Aruvant Sciences has announced the appointment of V. "Palani" Palaniappan (above) as Chief Technology Officer. In this role, Dr. Palaniappan will be charged with growing Aruvant's technical and manufacturing capabilities for current and future programs. With 25 years of research and drug development experience, including extensive work in chemistry, manufacturing and controls, Dr. Palaniappan will oversee the manufacturing of ARU-1801, a one-time, potentially curative investigational gene therapy for patients with sickle cell disease.

WuxiAppTec has appointed Dr. David Chang as Chief Executive Officer of its cell and gene therapy CDMO, WuXi Advanced Therapies. In this new executive role, Dr. Chang will provide strategic, scientific and operational leadership to the company's global cell and gene therapy R&D and manufacturing services. He was previously Corporate Vice President and Head of Cell Therapy Global Manufacturing at Celgene, where he oversaw the CAR-T manufacturing network and the global manufacturing sciences and technologies teams.

May 2020:

Immunomedics has announced that Harout Semerjian has decided to step down from his role as President and Chief Executive Officer. The biotech company says the decision, which is effective immediately, is "precipitated by the unfortunate significant logistical obstacles presented by the COVID-19 pandemic, including Mr. Semerjian’s ability to fully assume his duties as CEO." Dr. Behzad Aghazadeh, Executive Chairman of Immunomedics, will continue to support the Company in an executive leadership role going forward.

Late-stage biopharmaceutical firm Elevar Therapeutics has announced Mark Gelder as Vice President of Medical Affairs. Dr. Gelder will build and lead Elevar's global medical organization. Dr. Gelder has 17 years of global medical affairs experience leading therapeutic oncology programs for Pfizer, Wyeth and Bayer, where he was involved in the approval and launch of several cancer therapeutics.

Biopharmaceutical company Hoth Therapeutics has appointed Michael H. Peters to its Scientific Advisory Board. Dr. Peters is the inventor of Hoth's newly licensed Novel Peptide COVID-19 Therapeutic, to prevent spike protein binding, which may be a leading cause of COVID-19.

James M. Loar has been appointed chief commercial officer at CJB Applied Technologies, where he will head up global commercial activities related to innovation, contract development and manufacturing. He previously worked at Cool Planet for five years, most recently as president and chief executive officer.

North Carolina-based CDMO Alcami has named Brian Dillion as Vice President of Regulatory Affairs and Quality Assurance and Jacquelyn Uribe as Vice President of Quality Operations. “Jacque and Brian bring broad compliance expertise with a track record of success upholding the rigorous standards required by both customers and regulators in high growth environments,” commented Chief Financial Officer Eric Evans.

Clinical-stage drug discovery, development and manufacturing company Sutro Biopharma has appointed Craig Berman as Vice President of Clinical Development promoted Regina Cheng to Vice President of Finance and Controller. Dr. Berman has over 17 years of experience in drug development, including immuno-oncology, and most recently was Vice President of Clinical Development at QED Therapeutics.

Selexis SA has promoted Myriam Adam to Vice President, Operations and Intellectual Property; Séverine Fagète to Vice President, Cell Line Development Services; and Valérie Le Fourn to Vice President, Research.

CordenPharma has appointed William Cashin as Chief Quality & Compliance Officer and Dr. Lee Newton as Chief Operating Officer. Both were previously at Lonza, where Mr Cashin served as Global Head Quality, Mammalian & Microbial and where Dr. Newton most recently held the role of Senior Vice President and Business Unit Head for Lonza’s small molecule API business.

Do you have a pharmaceutical people move that you'd like to share? Please contact [email protected]

Related News